Increased PHOSPHO1 and alkaline phosphatase expression during the anabolic bone response to intermittent parathyroid hormone delivery

The administration of intermittent parathyroid hormone (iPTH) is anabolic to the skeleton. Recent studies with cultured osteoblasts have revealed that the expression of PHOSPHO1, a bone‐specific phosphatase essential for the initiation of mineralisation, is regulated by PTH. Therefore, this study sought to determine whether the bone anabolic response to iPTH involves modulation of expression of Phospho1 and of other enzymes critical for bone matrix mineralisation. To mimic iPTH treatment, primary murine osteoblasts were challenged with 50 nM PTH for 6 h in every 48 h period for 8 days (4 cycles), 14 days (7 cycles) and 20 days (10 cycles) in total. The expression of both Phospho1 and Smpd3 was almost completely inhibited after 4 cycles, whereas 10 cycles were required to stimulate a similar response in Alpl expression. To explore the in vivo role of PHOSPHO1 in PTH‐mediated osteogenesis, the effects of 14‐ and 28‐day iPTH (80 µg/kg/day) administration was assessed in male wild‐type (WT) and Phospho1−/− mice. The expression of Phospho1, Alpl, Smpd3, Enpp1, Runx2 and Trps1 expression was enhanced in the femora of WT mice following iPTH administration but remained unchanged in the femora of Phospho1−/− mice. After 28 days of iPTH administration, the anabolic response in the femora of WT was greater than that noted in Phospho1−/− mice. Specifically, cortical and trabecular bone volume/total volume, as well as cortical thickness, were increased in femora of iPTH‐treated WT but not in iPTH‐treated Phospho1−/− mice. Trabecular bone osteoblast number was also increased in iPTH‐treated WT mice but not in iPTH‐treated Phospho1−/− mice. The increased levels of Phospho1, Alpl, Enpp1 and Smpd3 in WT mice in response to iPTH administration is consistent with their contribution to the potent anabolic properties of iPTH in bone. Furthermore, as the anabolic response to iPTH was attenuated in mice deficient in PHOSPHO1, this suggests that the osteoanabolic effects of iPTH are at least partly mediated via bone mineralisation processes.

[1]  A. Koh,et al.  Anabolic actions of parathyroid hormone in a hypophosphatasia mouse model , 2022, Osteoporosis International.

[2]  A. Pitsillides,et al.  Increased PHOSPHO1 expression mediates cortical bone mineral density in renal osteodystrophy , 2021, bioRxiv.

[3]  C. Schalin-Jäntti,et al.  Physiology of Calcium Homeostasis: An Overview. , 2021, Endocrinology and metabolism clinics of North America.

[4]  C. Farquharson,et al.  Endocrinology of Bone and Growth Disorders , 2021, Reference Module in Biomedical Sciences.

[5]  L. Mccauley,et al.  Anabolic actions of PTH in murine models: two decades of insights , 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  L. Bonewald,et al.  Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23 , 2020, Calcified Tissue International.

[7]  J. Millán,et al.  How To Build a Bone: PHOSPHO1, Biomineralization, and Beyond , 2019, JBMR plus.

[8]  A. Boyde,et al.  A distinctive patchy osteomalacia characterises Phospho1‐deficient mice , 2017, Journal of anatomy.

[9]  C. Farquharson,et al.  The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures , 2016, Calcified Tissue International.

[10]  H. Yasuda,et al.  Smpd3 Expression in both Chondrocytes and Osteoblasts Is Required for Normal Endochondral Bone Development , 2016, Molecular and Cellular Biology.

[11]  R. Pacifici T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone , 2016, Annals of the New York Academy of Sciences.

[12]  J. Millán,et al.  Phospho1 deficiency transiently modifies bone architecture yet produces consistent modification in osteocyte differentiation and vascular porosity with ageing , 2015, Bone.

[13]  J. Millán,et al.  Alkaline Phosphatase and Hypophosphatasia , 2015, Calcified Tissue International.

[14]  M. Razzaque,et al.  Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity. , 2015, BoneKEy reports.

[15]  J. Bilezikian,et al.  Parathyroid hormone: anabolic and catabolic actions on the skeleton. , 2015, Current opinion in pharmacology.

[16]  A. Boyde,et al.  An Investigation of the Mineral in Ductile and Brittle Cortical Mouse Bone , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  L. Bonewald,et al.  The parathyroid hormone-regulated transcriptome in osteocytes: parallel actions with 1,25-dihydroxyvitamin D3 to oppose gene expression changes during differentiation and to promote mature cell function. , 2015, Bone.

[18]  J. Millán,et al.  Dual Role of the Trps1 Transcription Factor in Dentin Mineralization* , 2014, The Journal of Biological Chemistry.

[19]  C. Farquharson,et al.  Direct stimulation of bone mass by increased GH signalling in the osteoblasts of Socs2−/− mice , 2014, The Journal of endocrinology.

[20]  J. Millán The Role of Phosphatases in the Initiation of Skeletal Mineralization , 2013, Calcified Tissue International.

[21]  M. Selig,et al.  Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  H. Kiyonari,et al.  Osterix Regulates Calcification and Degradation of Chondrogenic Matrices through Matrix Metalloproteinase 13 (MMP13) Expression in Association with Transcription Factor Runx2 during Endochondral Ossification* , 2012, The Journal of Biological Chemistry.

[23]  A. Pitsillides,et al.  Extracellular Matrix Mineralization Promotes E11/gp38 Glycoprotein Expression and Drives Osteocytic Differentiation , 2012, PloS one.

[24]  N. Jørgensen,et al.  Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans , 2012, Scandinavian journal of clinical and laboratory investigation.

[25]  Y. Hannun,et al.  A cell-autonomous requirement for neutral sphingomyelinase 2 in bone mineralization , 2011, The Journal of cell biology.

[26]  B. Langdahl,et al.  Medical Treatment of Osteoporotic Vertebral Fractures , 2011, Therapeutic advances in musculoskeletal disease.

[27]  M. McKee,et al.  Loss of Skeletal Mineralization by the Simultaneous Ablation of PHOSPHO1 and Alkaline Phosphatase Function: A Unified Model of the Mechanisms of Initiation of Skeletal Calcification , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  Simon R. Goodyear,et al.  PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fractures. , 2010, Bone.

[29]  M. Karsdal,et al.  Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. , 2010, Bone.

[30]  G. Loots,et al.  Parathyroid Hormone (PTH)–Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  H. Ryoo,et al.  Upregulation of smpd3 via BMP2 stimulation and Runx2. , 2009, BMB reports.

[32]  N. Sims,et al.  EphrinB2 Regulation by PTH and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  R. Shivdasani,et al.  Uncoupling of chondrocyte differentiation and perichondrial mineralization underlies the skeletal dysplasia in tricho-rhino-phalangeal syndrome. , 2008, Human molecular genetics.

[34]  A. Parfitt,et al.  Perspective: Quantifying Osteoblast and Osteocyte Apoptosis: Challenges and Rewards , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  J. Parsons,et al.  Preliminary trial of low doses of human parathyroid hormone 1–34 peptide in treatment of osteoporosis , 1975, Calcified Tissue Research.

[36]  M. Kneissel,et al.  SOST is a target gene for PTH in bone. , 2005, Bone.

[37]  L. Gelbert,et al.  Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray , 2005, Journal of cellular biochemistry.

[38]  P. Sadler,et al.  Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities. , 2004, The Biochemical journal.

[39]  H. Anderson,et al.  Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. , 2004, The American journal of pathology.

[40]  L. Qin,et al.  Parathyroid hormone: a double-edged sword for bone metabolism , 2004, Trends in Endocrinology & Metabolism.

[41]  B. L. Riggs,et al.  Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone , 2003, Journal of cellular biochemistry.

[42]  E. Eriksen Primary hyperparathyroidism: lessons from bone histomorphometry. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  M. Rubin,et al.  The potential of parathyroid hormone as a therapy for osteoporosis. , 2002, International journal of fertility and women's medicine.

[44]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[45]  R. L. Cain,et al.  Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation. , 2001, Endocrinology.

[46]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[47]  R. L. Cain,et al.  Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. , 2001, Endocrinology.

[48]  R. Recker,et al.  On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. , 1999, The Journal of clinical endocrinology and metabolism.

[49]  A. Yamaguchi,et al.  Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. , 1997, The Journal of clinical investigation.

[50]  J. Millán,et al.  Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia , 1997, Developmental dynamics : an official publication of the American Association of Anatomists.

[51]  R. Terkeltaub,et al.  Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1. Relevance to calcium pyrophosphate dihydrate deposition disea , 1994, Arthritis and rheumatism.

[52]  E. Canalis,et al.  Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. , 1989, The Journal of clinical investigation.

[53]  J. Heersche,et al.  Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. , 1982, Endocrinology.